Celebrating 100 Partners in the Alloy Biotechnology Ecosystem
At Alloy we refer to ourselves as a biotechnology ecosystem company. We are building a network of collaborations among drug discovery teams, where knowledge and technology that can benefit the entirety of the ecosystem will be widely distributed and accessible by all. Our hope is that each new participant can make that system more vibrant […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
Alloy Therapeutics and Pyxis Oncology launched Voxall Therapeutics, a joint venture focused on developing novel immune-modulating antibody therapies for cancer and autoimmune diseases. The collaboration integrates Alloy’s ATX-Gx™ discovery platform with Pyxis’ target expertise and preclinical capabilities, facilitated by Alloy’s 82VS venture studio. LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and […]